Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis.

Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis.

Muscle-specific tyrosine kinase (MuSK) autoantibodies are the hallmark of a form of myasthenia gravis (MG) that can challenge the neurologist and the experimentalist. The clinical disease can be difficult to treat effectively. MuSK autoantibodies affect the neuromuscular junction in several ways. Wh...

Bibliografske podrobnosti
Main Authors:	Phillips, W, Christadoss, P, Losen, M, Punga, A, Shigemoto, K, Verschuuren, J, Vincent, A
Format:	Journal article
Jezik:	English
Izdano:	Academic Press Inc. 2015

Podobne knjige/članki

Myasthenia gravis with MuSK antibodies
od: Farrugia, M, et al.
Izdano: (2005)

The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.
od: Koneczny, I, et al.
Izdano: (2014)

The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis
od: Koneczny, I, et al.
Izdano: (2014)

Potential mechanisms in MuSK-myasthenia gravis
od: Koneczny, I
Izdano: (2014)

MuSK-Myasthenia Gravis Unmasked by Hydroxychloroquine
od: Shalini Bhaskar, et al.
Izdano: (2022-01-01)

Infantile Onset Myasthenia Gravis with MuSK Antibodies
od: J Gordon Millichap
Izdano: (2006-08-01)

The prevalence of MuSK antibody positive myasthenia gravis worldwide
od: Vincent, A, et al.
Izdano: (2006)

Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.
od: McConville, J, et al.
Izdano: (2004)

MuSK antibody-positive, seronegative myasthenia gravis in Korea.
od: Lee, J, et al.
Izdano: (2006)

MuSK Antibody Positive Myasthenia Gravis Mimicking as Myositis
od: Nilesh Wagh, et al.
Izdano: (2024-09-01)

MuSK-Associated Myasthenia Gravis: Clinical Features and Management
od: Carmelo Rodolico, et al.
Izdano: (2020-07-01)

Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models
od: Jamie L. Lim, et al.
Izdano: (2025-02-01)

MuSK-antibody-positive myasthenia gravis in a South Asian population.
od: Chang, T, et al.
Izdano: (2009)

Anti-MuSK antibodies in a case of ocular myasthenia gravis.
od: Bennett, D, et al.
Izdano: (2006)

Anti-MuSK antibody positive myasthenia gravis with childhood onset
od: Diana Epure, et al.
Izdano: (2016-06-01)

Progress in rituximab for anti⁃MuSK antibody-related myasthenia gravis
od: Ting LI, et al.
Izdano: (2020-01-01)

Clinical Characteristics of MuSK Antibody-positive Myasthenia Gravis in Taiwan
od: Yung-Chuan Huang, et al.
Izdano: (2008-07-01)

Anti-MuSK antibodies in seronegative myasthenia gravis: a cause of denervation
od: Newsom-Davis, J, et al.
Izdano: (2001)

Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5.
od: Niks, E, et al.
Izdano: (2006)

Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese.
od: Yeh, J, et al.
Izdano: (2004)

Targeted treatment approaches and pathogenicity of antibody subclasses in MuSK-myasthenia gravis
od: Cao, M
Izdano: (2021)

Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation
od: Fangyi Shi, et al.
Izdano: (2024-11-01)

Coexistence of anti-MuSK antibody-positive myasthenia gravis and rheumatoid arthritis
od: Amber Eker, et al.
Izdano: (2020-08-01)

Regional Features of MuSK Antibody-Positive Myasthenia Gravis in Northeast China
od: Zunwei Zhang, et al.
Izdano: (2020-10-01)

Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.
od: Shiraishi, H, et al.
Izdano: (2005)

Myasthenia Crisis as First Presentation of MuSk Positive Myasthenia Gravis: A Case Report
od: Dipesh Chhetri, et al.
Izdano: (2025-02-01)

Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis
od: Lee, J, et al.
Izdano: (2016)

Anti-MuSK-Positive Myasthenia Gravis in a Patient with Parkinsonism and Cognitive Impairment
od: S. Lanfranconi, et al.
Izdano: (2011-01-01)

MuSK Myasthenia Gravis—Potential Pathomechanisms and Treatment Directed against Specific Targets
od: Edyta Dziadkowiak, et al.
Izdano: (2024-03-01)

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience
od: Christiane Schneider-Gold, et al.
Izdano: (2017-10-01)

Quantitative EMG studies to assess facial muscle atrophy in MuSK antibody positive myasthenia gravis
od: Farrugia, M, et al.
Izdano: (2007)

Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease
od: Aigli G. Vakrakou, et al.
Izdano: (2023-07-01)

Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK.
od: Vuslat Yilmaz, et al.
Izdano: (2015-01-01)

Anti-MuSK antibody positive myasthenia gravis with Graves disease: one case report
od: Shan CAO, et al.
Izdano: (2019-02-01)

MuSK Myasthenia Gravis in an HIV-infected Chinese old man successfully treated with pyridostigmine
od: Yirui Xie, et al.
Izdano: (2020-09-01)

Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis.
od: Deymeer, F, et al.
Izdano: (2007)

MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
od: Farrugia, M, et al.
Izdano: (2006)

Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1.
od: Niks, E, et al.
Izdano: (2008)

A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression
od: Koneczny, I, et al.
Izdano: (2024)

Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
od: Hoch, W, et al.
Izdano: (2001)